Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    (3S,4R)-4-((5-Chloro-4-(4-fluoro-2-(2-hydroxypropan-2-yl)-1-isopropyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Relay Therapeutics Reports Q1 2026 Results and Corporate Updates
    Relay Therapeutics Reports Q1 2026 Results and Corporate Updates

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3288234/0/en/relay-therapeutics-reports-first-quarter-2026-financial-results-and-corporate-updates.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Relay Report Clinical Data Supporting Triplet Combo in MBC Cancer
    Relay Report Clinical Data Supporting Triplet Combo in MBC Cancer

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3281389/0/en/relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-supportive-of-further-development-in-frontline-metastatic-breast-cancer.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    Pfizer’s Ibrance Heir Reduces Risk of Death in Ph 2 Breast Cancer
    Pfizer’s Ibrance Heir Reduces Risk of Death in Ph 2 Breast Cancer

    17 Mar 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/pfizers-ibrance-heir-reduces-risk-of-death-in-phase-2-breast-cancer-test

    BIOSPACE
    17 Mar 2026
    Share Share
    Olema Oncology Reveals 2025 Financial Results
    Olema Oncology Reveals 2025 Financial Results

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256109/0/en/Olema-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-and-Operating-Results.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Olema Oncology, Pfizer Partner to Combine Palazestrant
    Olema Oncology, Pfizer Partner to Combine Palazestrant

    02 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/02/3142485/0/en/Olema-Oncology-Announces-New-Clinical-Trial-Agreement-with-Pfizer-to-Combine-Palazestrant-with-Atirmociclib-in-ER-HER2-Metastatic-Breast-Cancer.html

    GLOBENEWSWIRE
    02 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.